Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STERLING WILL PAY FTC $375,000 TO SETTLE MIDOL COMPLAINT

Executive Summary

STERLING WILL PAY FTC $375,000 TO SETTLE MIDOL COMPLAINT charging the company with making "unsubstantiated therapeutic performance claims" in ads for the OTC menstrual pain relief brand. The Federal Trade Commission said June 12 that the ads violated a 1985 ruling that bars such claims unless a company has a "reasonable basis" for substantiation. The agreement was reached in March but was not announced until after the FTC complaint was filed in D.C. federal court on June 8. The commission announced that Sterling has agreed to pay$375,000 in civil penalties to settle the charges under a consent decree agreement, which does not constitute an admission of wrongdoing. The company said it believes its Midol claims were "adequately supported" but chose not to litigate the matter. None of the ads that were the basis of the FTC complaint is now running. The complaint stems from certain ads that ran from March 1985 to January 1986 and again in April 1988 for Original Formula Midol and Maximum Strength Midol for Cramps as well as Spanish-language ads that ran in the spring of 1986 for Maximum Strength Midol PMS and again in November 1988 for Original Midol Multi-Symptom Formula and Maximum Strength Midol Multi-Symptom Formula. The first series of TV and print ads were cited by the FTC for making unsubstantiated therapeutic performance claims, "directly or by implication," that one active ingredient in the formulation at the time, cinnamedrine HCl, "helps relieve muscle contractions fast and is a muscle relaxant for menstrual cramps." Cinnamedrine was categorized by FDA as a Category III smooth muscle relaxant in the OTC Menstrual Products Tentative Final Monograph published in November 1988. The ingredient is no longer in the Midol formulation. The complaint also takes Sterling to task for Maximum Strength Midol PMS ads that ran in the spring of 1986, claiming that the product provides "total" or "complete relief" from all symptoms of premenstrual syndrome. Finally, FTC said that ads that ran in November 1988 for Midol regular and maximum strength Multi-Symptom Formula made unsubstantiated claims that the products have a combination of ingredients "that relieves menstrual bloating or water weight gain." The 1985 order, which set a two-tiered system for substantiating OTC analgesic superiority claims, settled a longstanding "established superiority" ad claims case from the mid-1970s that involved not only Midol, but also Sterling ads for its analgesics Bayer Aspirin, Bayer Children's Aspirin, Vanquish and Cope. That ruling actually was made in 1983 ("The Pink Sheet" July 16, 1983, p. 7), but did not go into effect until March 25, 1985, when the Supreme Court denied Sterling's writ of certiorari. The Sterling order modified an earlier ruling, made in 1981, that all superiority claims for American Home Products' Anacin/Arthritis Pain Formula had to be substantiated by two double-blind, placebo-controlled clinical trials. The Sterling decision set up a two-tiered system that required two or more adequate and well-controlled clinical trials only for claims that one product has "established" superior effectiveness over competing products. That two-tiered system is still the standard for FTC cases and most recently was cited in a Sept. 28, 1989 complaint involving Schering's weight-loss product Fibre Trim.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017636

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel